Abstract
Study design must always depend on the objectives of the trial. In this paper, I will be talking about trials in phase II, III, and IV that are intended to determine whether a drug is safe and effective for use in altering lipids and lipoproteins for prevention of coronary artery disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Breier, C.H., Drexel, H., Lisch, H.J., Muhlberger, V., Herold, M., Knapp, E., Braunsteiner, H., Lancet 1985, 1:1242–1244
Boers, G.H.J., Smals, A.G.H., Trijbels, F.J.M., Fowler, B., Bakkeren, J.A.J.M., Schoonderwaldt, M.D., Kleijer, W.J., Kloppenborg, P.W.C., New Engl J Med 1985, 313:709–715
Barrett-Connor, E.,Khaw, K., Yen, S., New Engl J Med 1986, 315:1519–1524
Lipid Research Clinics Program, JAMA 1984, 251:351–364
Canner, P.L., Berge, K.G., Wenger, N.K., Stamler, J., Friedman, L., Prineas, R.J., Friedewald, W., J Am Coll Cardiol 1986, 8:1245–1255
Committee of Principal Investigators, Br Heart J 1978, 40:1069–1118
The Coronary Drug Project Research Group, JAMA 1970, 214:1303–1313
The Coronary Drug Project Research Group, JAMA 1972, 220:996–1008
The Coronary Drug Project Research Group, JAMA 1973, 226:652–657
Multiple Risk Factor Intervention Trial ResearchGroup, JAMA 1982, 248:1465–1477
University Group Diabetes Program, Diabetes 1970, 19:789–815
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Troendle, G. (1989). What Levels of Cholesterol should be Studied and What Should be the Study Designs?. In: Morganroth, J., Moore, E.N. (eds) Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents. Developments in Cardiovascular Medicine, vol 100. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1605-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1605-3_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8888-6
Online ISBN: 978-1-4613-1605-3
eBook Packages: Springer Book Archive